Embera NeuroTherapeutics, Inc. To Receive Grant For Clinical Trial Through New Crowd Funding Platform

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOSTON & SHREVEPORT, La.--(BUSINESS WIRE)--Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for smoking cessation and other addictions, today announced that Sound Affects Life, a 501(c)3 not-for-profit charity, has selected Embera as part of its inaugural group of companies to receive a grant funded by contributions through Soundaffectslife.org. Soundaffectslife.org, which launches today, is a new crowd funding platform designed to connect individuals with organizations that are actively seeking improved outcomes in cancer. The grant will support the evaluation of EMB-001, the company’s lead drug candidate, in a Phase 1 clinical trial enrolling individuals who smoke but are otherwise healthy.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC